1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

GLENMARK.BO
Glenmark Pharmaceuticals LimitedIN flagBombay Stock Exchange
2,263.45
INR
-7.00
- -
639.45BMarket Cap
Glenmark Pharmaceuticals Limited
GLENMARK.BO
(Bombay Stock Exchange)

Recent

price

2,263.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
109.21
148.7
183.57
218.56
240.42
262.53
314.13
316.96
343.95
368.48
382.96
431.45
405.15
412.37
465.9
592.2
592.12
Revenue per Share
16.95
17.03
22.91
20.01
17.52
25.01
32.46
27.44
32.78
27.5
34.38
33.37
10.53
-53.22
37.11
48.26
48.25
Basic EPS, GAAP
19.61
19.19
23.94
31.5
17.76
12.28
23.3
58.41
46.93
16.34
12.63
11.29
0.62
-41.25
-55.94
73.97
- -
Free Cash Flow per Basic Share
0.47
0.47
2.37
2.33
2.34
2.42
2.4
2.41
2.41
2.43
2.5
3.29
4.84
4.17
2.5
5
- -
Dividend per Share
50.62
66.24
84.75
100.61
114.27
134.13
163.38
188.55
199.99
225.32
257.36
327.43
336.16
279.93
312.83
1
1
Book Value per Share
38.18
45.88
55.91
61.38
63.73
98.57
127.78
144.54
137.07
137.79
167.61
253.49
263.07
230.82
261.86
283.69
283.65
Tangible Book Value per Share
270
270
271
271
271
281
282
282
282
282
282
282
282
282
282
282
282
Basic Weighted Avg Shares
29,491
40,206
49,691
59,236
65,216
73,700
88,638
89,436
97,051
103,972
108,060
121,742
114,319
116,355
131,458
167,114
167,114
Sales/Revenue/Turnover
21.64
15.33
18.54
14.92
11.69
15.79
16.47
14.13
12.98
12.33
15.88
15.11
9.44
5.42
14.19
23.93
23.93
Operating Margin (%)
947
978
1,270
2,168
2,600
2,691
5,765
3,541
3,259
4,172
4,436
4,867
6,113
6,308
4,860
5,735
5,735
Depreciation Expense
4,578
4,603
6,200
5,423
4,753
7,021
9,160
7,742
9,250
7,760
9,700
9,417
2,972
-15,017
10,471
13,619
13,619
Net Income, GAAP
4.92
4.87
14.98
21.71
20.03
30.14
27.32
27.42
28.88
29.2
29.83
31.06
137.34
5,116.71
25.16
31.38
31.38
Effective Tax Rate (%)
15.52
11.45
12.48
9.15
7.29
9.53
10.33
8.66
9.53
7.46
8.98
7.74
2.6
-12.91
7.97
8.15
8.15
Profit Margin (%)
3,397
10,454
15,254
18,135
16,120
19,044
41,708
37,008
26,757
26,776
31,586
35,929
56,205
16,095
33,284
49,233
49,233
Working Capital
6,171
13,125
19,203
24,287
25,744
24,873
45,363
41,418
35,738
42,743
41,129
27,717
40,293
1,517
6,989
4,863
4,863
LT Debt
20,639
24,266
27,874
29,966
30,001
42,699
49,390
55,887
56,048
60,701
70,643
94,381
98,393
78,475
88,491
105,118
105,118
Total Equity
14.42
13.26
15.27
11.6
9.26
10.77
11.87
9.26
8.87
8.55
10.38
10.01
-2.9
-267.81
13.65
24.48
24.48
Return on Invested Capital (%)
22.73
15.76
16.36
12.38
9.72
11.29
12.74
10.17
11.6
9.64
10.24
8.49
0.62
-232.79
11.77
25.25
25.25
Return on Capital (%)
65.69
29.15
30.36
21.6
16.32
20.45
21.87
15.59
16.87
12.93
14.24
11.41
3.17
-17.28
12.52
30.76
30.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
4,466
- -
1,072
LT Borrowings
5,328
- -
- -
LT Finance Leases
2,448
- -
4,863
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
282
- -
282
Market Capitalization
555,234
578,869
602,082

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
114,532
- -
112,997
Cash, Cash Equivalents & STI
29,583
- -
14,010
Accounts Receivable, Net
37,731
- -
49,634
Inventories
32,807
- -
34,308
Total Current Liabilities
69,595
- -
63,764
Payables & Accruals
- -
- -
- -
ST Debt
4,466
- -
1,072
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.29%
9.83%
18.79%
Free Cash Flow
-686.97%
-1,400.7%
-232.25%
Net Income, GAAP
-77.29%
-163.25%
30.06%
Sales/Revenue/Turnover
8.92%
9.69%
27.12%
Total Cash Common Dividend
- -
25.04%
100.21%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29,985
31,607
24,603
30,160
116,355
2025
32,233
34,005
33,019
32,201
131,458
2026
30,593
60,038
38,880
37,603
167,114

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.31
-2.9
-12.45
- -
-53.22
2025
12.06
12.55
12.33
0.16
37.11
2026
1.66
21.63
14.29
10.68
48.26

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.17
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
5
Similar Companies
Desh Rakshak Aushdhalaya Ltd. (DESHRAK.BO)
China National Medicines Corporation Ltd. (600511.SS)
BioGaia AB (publ) (BIOGY)
Organogenesis Holdings Inc. (ORGO)
Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
Onassis Holdings Corp. (ONSS)
Business
Glenmark Pharmaceuticals Limited (GLENMARK.BO), a research-led global integrated pharmaceutical company headquartered in Mumbai, India, and founded in 1977, develops, manufactures and markets branded formulations, generics and over-the-counter (OTC) products with a focus on dermatology, respiratory, oncology, cardio-metabolic, central nervous system and other therapeutic areas including diabetes, cardiovascular and infectious diseases. The company offers innovative specialty products such as RYALTRIS nasal spray and Winlevi clascoterone cream; generic formulations encompassing oral solids, injectables like Acetylcysteine Injection, Ropivacaine Hydrochloride Injection, Vancomycin Hydrochloride for Injection, Eribulin Mesylate Injection and Micafungin for Injection, nasal sprays, ophthalmic solutions like Olopatadine Hydrochloride and Latanoprost, topical foams such as Clindamycin Phosphate Foam, emulsions including Phytonadione Injectable and Epinephrine Injection, OTC offerings like Polyethylene Glycol 3350 powder and Mixed Amphetamines Immediate-Release Tablets; and partnered oncology drugs including Tislelizumab, Zanubrutinib, BRUKINSA, TEVIMBRA and Hengrui’s HER2-targeting ADC. Glenmark operates 14 manufacturing facilities across four countries, four state-of-the-art R&D centers, and maintains commercial presence in over 80 countries with more than 60% of revenue from international markets, primarily the United States, Europe, India, Brazil, Russia, Latin America and Africa, supported by subsidiaries like Glenmark Pharmaceuticals Inc. USA and Ichnos Glenmark Innovation (IGI). Recent developments include a May 2024 partnership with BeiGene for marketing Tislelizumab and Zanubrutinib in India; a July 2025 global licensing agreement between IGI and AbbVie for ISB 2001, a trispecific antibody for multiple myeloma; market authorizations for Winlevi in 15-17 European countries with Cosmo Pharmaceuticals; China approval for RYALTRIS; US FDA approvals and launches of eight Abbreviated New Drug Applications (ANDAs) in FY2025 including injectables and OTC products; launches of Nebzmart GFB Smartules and Glenmark Airz FB Smartules as the world’s first nebulized triple therapy for COPD; expansion of the cardiometabolic portfolio with Empagliflozin and fixed-dose combinations in India; acquisition of a 34% stake in O2 Renewable Energy XXIV Private Limited in December 2024 for renewable energy compliance; and initiation of a Phase 3 trial for Envafolimab in non-small cell lung cancer.